by Lou | Jul 28, 2026 | Press Releases
CORE Biomedicine Signs Exclusive Licensing Agreement with Eisai for Precision Oncology Programs FollowFollow BOSTON, MA, USA and TOKYO, Japan — July 28, 2026 — CORE Biomedicine, an innovative drug discovery company developing next-generation precision medicines for...
by Lou | Jul 28, 2026 | Press Releases
CORE Biomedicine Secures $21 Million Series A Venture Financing and Receives AMED Grant Award to Advance Novel Cancer Therapeutics The venture financing and AMED grant funding position CORE to accelerate development of novel lineage-based oncology therapies for...
by Lou | Sep 15, 2025 | Press Releases
CORE Biomedicine, Inc. Selected to Present at the 2025 ALIGN Summit Hosted by MassBio FollowFollow Boston, MA – Sep 15, 2025 — CORE Biomedicine, Inc. is proud to announce its selection as a presenting company at the prestigious 2025 ALIGN Summit, an annual life...
by Lou | Jun 1, 2025 | Press Releases
CORE Biomedicine, Inc. Selected to Present at LUMINESCENCE During the 2025 BIO Convention in Boston, MA FollowFollow Boston, MA –Jun 1, 2025 — CORE Biomedicine, Inc., an innovative biotechnology company advancing transformative approaches in oncology, is honored to...
by Lou | May 27, 2025 | Press Releases
CORE Biomedicine, Inc. Named Finalist in the 2025 Harvard Presidents Innovation Challenge FollowFollow Boston, MA — Mar 27, 2025 — CORE Biomedicine, Inc. is proud to announce that it has been selected as an official Finalist in the prestigious 2025 Harvard Presidents...
